Richard Pazdur, FDA Cancer Chief, Discusses 25 Years of Innovation
Dr. Richard Pazdur for 25 years has overseen innovations in the treatment of deadly diseases at the agency.
Related Articles
The Evolving Role of ctDNA in Guiding Adjuvant Chemotherapy Decisions in CRC: Insights from Stacey A. Cohen, MD
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
FDA Grants Priority Review to Avutometinib/Defactinib Combo in KRAS+ Ovarian Cancer
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
DLL3 Inhibitor Licensed to Roche
Innovent Biologics will license IBI3009, its investigational DLL3-targeted antibody–drug conjugate (ADC) for small cell lung cancer (SCLC), to Roche for $80 million upfront and payments…
Multiple Myeloma Patients Report Persistent Pain and Opioid Use During Remission
Many patients with multiple myeloma experience persistent pain and use opioids to manage that pain even after they achieve remission, a survey suggests.
Generic Platinum Chemotherapy Shortages Did Not Increase Deaths
A national data analysis published by researchers from Penn Medicine reported that short-term mortality was not impacted for patients with advanced cancers during the shortage…
AACR-QuadW Foundation Sarcoma Research Fellowship in Memory of Willie Tichenor
The one-year grant of $50,000 supports a postdoctoral or clinical research fellow conducting translational or clinical sarcoma research.
Addressing Tumor-Specific Training Needs of the CNS in Uro-Oncology – Oncology Nurse Advisor
A discussion paper on the role of the clinical nurse specialist in uro-oncology noted challenges due to a lack of consistent definition of the role,…
